NCT07089784 - Multiple Dose Study of MK-2828 in Participants With Type 2 Diabetes (MK-2828-003) | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

September 22, 2025

Primary Completion Date

January 12, 2026

Study Completion Date

January 12, 2026

Conditions

Diabetes Mellitus, Type 2

Interventions

DRUG

MK-2828

Oral capsule of MK-2828 taken once per day for 28 days.

DRUG

Placebo

Placebo to match MK-2828 oral capsule, taken once per day for 28 days.

Trial Locations (8)

RECRUITING

Jacksonville Center for Clinical Research ( Site 0002), Jacksonville

RECRUITING

Velocity Clinical Research, Hallandale Beach ( Site 0010), Hallandale

RECRUITING

QPS Miami Research Associates ( Site 0005), South Miami

RECRUITING

Advanced Pharma CR, LLC ( Site 0001), Miami

RECRUITING

AMR Lexington ( Site 0012), Lexington

RECRUITING

Alliance for Multispecialty Research, LLC ( Site 0013), Kansas City

RECRUITING

Bio-Kinetic Clinical Applications, LLC dba QPS-MO ( Site 0009), Springfield

RECRUITING

ProSciento Inc. ( Site 0004), Chula Vista

All Listed Sponsors

lead

Merck Sharp & Dohme LLC

INDUSTRY